CoChat

A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment

Open access
Jing, Xiao · 2024 · Academic Journal of Science and Technology

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 16 of the 28 sources its claims cite were checked for support.

Abstract

The appearance of CRISPR/Cas9 gene editing technology marks a revolutionary advance in the field of gene editing. With its high degree of specificity and efficiency, this technology enables precise modification of genome-specific loci. This paper reviews the mechanism of CRISPR/Cas9 and its applications in various fields such as genetic disease treatment, cancer therapy, antiviral therapy, gene function research and virus detection. Also, the challenges of off-target effects are discussed and strategies to minimize them are proposed, The purpose of this study is to propose applications and innovations of CRISPR/Cas9 technology in medical therapeutics while addressing its current limitations.

Overview

CoChat Summary

TL;DR

This review describes the CRISPR/Cas9 mechanism and its applications in hereditary disease, cancer, antiviral therapy, gene function research, and virus detection, while outlining challenges such as off-target effects. It concludes that CRISPR/Cas9 is a flexible genome-editing tool with therapeutic promise, but clinical translation requires improved specificity, delivery, safety, and ethical/regulatory oversight.

Key findings

  • The review outlines the CRISPR/Cas9 mechanism: sgRNA guides Cas9 to target DNA; Cas9 cuts 3 bp upstream of the PAM, producing a blunt double-strand break; repair occurs via NHEJ (indels) or HDR (precise editing). CRISPR arrays contain repeat sequences of 25–35 bp separated by spacer sequences of 30–40 bp.
  • Applications discussed include hereditary diseases (sickle cell anemia, β-thalassemia, DMD, familial hypercholesterolemia via PCSK9), cancer immunotherapy (PD-1 knockout), antiviral therapy (HIV-1 LTR targeting), gene function studies (p53 knockout mice), and virus detection (SHERLOCK for SARS-CoV-2 and dengue).
  • Cited examples: Tabebordbar used AAV-delivered CRISPR/Cas9 in an mdx mouse model to delete mutated exon 23, restoring the Dmd reading frame; Rupp et al. found PD-1 knockout T cells had stronger anti-tumor effects and significantly prolonged mouse survival; Ebina’s group reduced HIV-1 LTR-driven expression and removed latent HIV-1 provirus; p53 knockout mice showed high spontaneous tumorigenesis including lymphomas and osteosarcomas.
  • The paper identifies off-target effects, delivery, immune response, genetic stability, and ethical issues as main challenges, and proposes optimizing sgRNA design, Cas9 variants, and safer delivery systems.

Methods

  • Design: narrative review of CRISPR/Cas9 gene editing technology and its disease-treatment applications.
  • Data/sample: no primary experimental sample or dataset; the paper synthesizes published studies and cited examples across genetic disease, cancer, antiviral, gene function, and virus detection.
  • Main analysis: descriptive synthesis of mechanism and applications; no systematic search strategy, inclusion criteria, or quantitative/meta-analytic analysis is described.

Limitations

  • The paper states challenges including off-target effects, delivery issues, immune response, genetic stability, and ethical controversies, especially in embryos and germ cells.
  • The paper states that off-target effects remain an important concern despite sgRNA design and Cas9 variant improvements, and that long-term safety assessments and ethical/regulatory frameworks are needed.
  • Evident from the text: as a review, it lacks a described systematic search or quantitative synthesis; citation numbering in the text appears inconsistent with the reference list (e.g., Tabebordbar, PCSK9, p53, and SHERLOCK citations), limiting verifiability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.54097/5crj2x50

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

3 Valid · 13 Not valid · 12 Not checked · 4 Own results and interpretations

12 more claims · 4 with their cited sources checked

Create a free account to see all 32 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Research works printed but not linked: 2

  1. [2]2. Wang, L., & Zhao, T. (2017). The principle of CRISPR/Cas9 and its research progress in disease treatment. *Developmental Medicine Electronic Journal*, (1), 35-44.
  2. [3]3. Huang, J., & Fang, S. (2024). Advances in molecular diagnostics applications based on the CRISPR-Cas system. *Journal of Molecular Diagnostics and Therapy*, (6), 989- 992+1001. https://doi.org/10.19930/j.cnki.jmdt.2024.06.004 · doi:10.19930/j.cnki.jmdt.2024.06.004

Cited by

See all 1

Metadata

Authors
Jing, X.
Affiliations
Beijing University of Chemical Technology (CN)
Corresponding author
Jing, Xiao
Venue
Academic Journal of Science and Technology
Published
2024-12-26
Volume
13
Issue
3
Pages
132-134
ISSN
2771-3032 (ISSN-L)
OpenAlex
W4405808461
Cited by
0
References
11
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
Academic Journal of Science and Technology (publishedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9, genome editing, genetic disease treatment, cancer therapy, antiviral therapy, virus detection, off-target effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.